Skip to main content
. Author manuscript; available in PMC: 2022 Apr 19.
Published in final edited form as: Atheroscler Plus. 2021 Aug 21;44:31–42. doi: 10.1016/j.athplu.2021.08.005

Fig. 4.

Fig. 4.

Smad2 and p53 enrich in the same region of MET promoter.

A. p53 activation with nutlin3a enhances the Smad2 function of inhibiting MET promoter activity (luciferase assay).

B and C. Smad2 and p53 co-occupy in the same MET promoter region (ChIP-qPCR).

Human primary aortic SMCs (AoSMCs) culture, transfection, and data quantification were performed as described for Fig. 1. Cells were treated with nutlin3a for 2 h before harvest. Mean ± SD, n = 3 repeats. Statistics: One-way ANOVA/Bonferroni post-hoc test; **P < 0.01, ***P < 0.001.